As Covid variants keep on spreading across the world, Eli Lilly laboratories has seen their approval removed for marketing bamlanivimab, as a monotherapy, being a therapy based on monoclonal antibodies. Why? Its effectiveness challenged by new coronavirus strains. Keep reading to find out more!